Legend Biotech Corporation (LEGN) has been in the news with mixed reviews. H.C. Wainwright lowered price target to $50 but maintained Buy rating due to Q4 Carvykti sales missing consensus. TD Cowen downgraded LEGN to Hold, citing sluggish demand for Carvykti influenced by toxicity concerns and competition.

Legend Biotech Corporation (LEGN) focuses on developing CAR‑T treatments for cancer, like CARVYKTI for multiple myeloma. Collaborations with partners like Johnson & Johnson help expand therapeutic impact. Despite potential, some believe other AI stocks offer greater upside potential with less downside risk.

For more investment opportunities, consider checking out the 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Read more at Yahoo Finance: H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)’s Carvykti Despite Sales Miss